Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.89 CHF | -0.90% |
|
-0.90% | +17.85% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+17.85% | 15.38B | |
+20.37% | 43.54B | |
+19.44% | 21.78B | |
+25.55% | 15.12B | |
+60.99% | 13.36B | |
-0.05% | 6.79B | |
-15.02% | 6.38B | |
-8.87% | 5.73B | |
+8.17% | 5.32B | |
+26.36% | 4.58B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars